Long-term safety was stable without emergent signals; grade ≥3 TRAEs stayed ~57–59%, while cumulative neuropathy increased with duration, managed via interruptions and EV dose reductions. Notably, ...

Bicycle Therapeutics trades below net cash, reflecting market skepticism on future cash burn and delayed commercialization.

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Updated data across two dose levels of 200 mW/cm and 400 mW/cm in LA-PDAC trial show 71% (5/7) patients resected following ...

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present multiple clinical study results of its novel Nectin-4-targeting ADC ...

Junshi Biosciences receives approval of toripalimab NDA from NMPA for first-line treatment of HER2 expressing urothelial carcinoma: Shanghai Saturday, May 23, 2026, 17:00 Hrs [IST ...

Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed Primary ...

A major international study has found that long-term exposure to arsenic may increase the risk of developing several types of urologic cancers. Researchers say the findings highlight the need for ...

Eli Lilly and Company (NYSE: LLY) today announced the details of presentations from across its oncology portfolio at the ...

Early report on modular BioVAT patches in advanced stage C or D disease ...

US FDA approves AstraZeneca’s Imfinzi for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer: Cambridge, UK Saturday, May 30, 2026, 13:00 Hrs [IST] AstraZene ...

Exposure to arsenic, cadmium and vanadium is linked to increased urologic cancer risk in a major meta-analysis. Read more on ...